Loading...

MedMira

DB:47M
Snowflake Description

Worrying balance sheet with weak fundamentals.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
47M
DB
CA$10M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific. The last earnings update was 20 days ago. More info.


Add to Portfolio Compare Print
  • MedMira has significant price volatility in the past 3 months.
47M Share Price and Events
7 Day Returns
-66.9%
DB:47M
1.1%
DE Medical Equipment
2.5%
DE Market
1 Year Returns
-77.8%
DB:47M
16.6%
DE Medical Equipment
-6.7%
DE Market
47M Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
MedMira (47M) -66.9% -66.7% 300% -77.8% -77.8% -91.3%
DE Medical Equipment 1.1% -0.3% 10.8% 16.6% 81.1% 196.4%
DE Market 2.5% 3.3% 9.2% -6.7% 9% 13.5%
1 Year Return vs Industry and Market
  • 47M underperformed the Medical Equipment industry which returned 16.6% over the past year.
  • 47M underperformed the Market in Germany which returned -6.7% over the past year.
Price Volatility
47M
Industry
5yr Volatility vs Market

47M Value

 Is MedMira undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.

In this section, we usually try to help investors determine whether MedMira is trading at an attractive price based on the cash flow it is expected to produce in the future. But as MedMira has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.

This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.

Show me the analysis anyway

INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for MedMira. This is due to cash flow or dividend data being unavailable. The share price is €0.004.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for MedMira's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are MedMira's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:47M PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-01-31) in CAD CA$0.00
TSXV:MIR Share Price ** TSXV (2019-04-18) in CAD CA$0.02
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 32.49x
Germany Market PE Ratio Median Figure of 421 Publicly-Listed Companies 19.69x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of MedMira.

DB:47M PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= TSXV:MIR Share Price ÷ EPS (both in CAD)

= 0.02 ÷ 0.00

-4.29x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MedMira is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • MedMira is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does MedMira's expected growth come at a high price?
Raw Data
DB:47M PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -4.29x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.68x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for MedMira, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on MedMira's assets?
Raw Data
DB:47M PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-01-31) in CAD CA$-0.02
TSXV:MIR Share Price * TSXV (2019-04-18) in CAD CA$0.02
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.23x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.87x
DB:47M PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= TSXV:MIR Share Price ÷ Book Value per Share (both in CAD)

= 0.02 ÷ -0.02

-0.79x

* Primary Listing of MedMira.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • MedMira has negative assets, we can't compare the value of its assets to the DE Medical Equipment industry average.

Next steps:

  1. Take a look at our analysis of 47M’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. When valuing a company like this, investors focus more on how they perceive the size of the opportunity, the company's ability to deliver and scale, and the strength of the team. While we are not analysing this type of data at the moment, if you don’t know where to start, we recommend reading through MedMira's regulatory filings and announcements.
  3. Show me more potentially undervalued companies in the Medical Equipment industry
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Value checks
We assess MedMira's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. MedMira has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

47M Future Performance

 How is MedMira expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as MedMira has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
11.9%
Expected Medical Equipment industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is MedMira expected to grow at an attractive rate?
  • Unable to compare MedMira's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare MedMira's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare MedMira's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:47M Future Growth Rates Data Sources
Data Point Source Value (per year)
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 11.9%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:47M Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in CAD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:47M Past Financials Data
Date (Data in CAD Millions) Revenue Cash Flow Net Income *
2019-01-31 1 -1 -2
2018-10-31 1 -1 -2
2018-07-31 1 -1 -3
2018-04-30 1 -1 -3
2018-01-31 1 -1 -3
2017-10-31 1 -2 -2
2017-07-31 1 -2 -3
2017-04-30 0 -2 -4
2017-01-31 0 -3 -5
2016-10-31 1 -3 -5
2016-07-31 2 -4 -5
2016-04-30 5 -5 -4

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if MedMira is high growth as no earnings estimate data is available.
  • Unable to determine if MedMira is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:47M Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (2 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from MedMira Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:47M Past Financials Data
Date (Data in CAD Millions) EPS *
2019-01-31 0.00
2018-10-31 0.00
2018-07-31 0.00
2018-04-30 0.00
2018-01-31 0.00
2017-10-31 0.00
2017-07-31 0.00
2017-04-30 -0.01
2017-01-31 -0.01
2016-10-31 -0.01
2016-07-31 -0.01
2016-04-30 -0.01

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if MedMira will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Take a look at our analysis of 47M’s management and see if the CEO’s compensation is within a reasonable range, who is on the board and if insiders have been trading lately.
  2. MedMira's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. MedMira's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess MedMira's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
MedMira has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

47M Past Performance

  How has MedMira performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare MedMira's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • MedMira does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare MedMira's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare MedMira's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
MedMira's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from MedMira Company Filings, last reported 2 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:47M Past Revenue, Cash Flow and Net Income Data
Date (Data in CAD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-01-31 0.55 -2.30 1.25 0.36
2018-10-31 0.60 -2.42 1.33 0.48
2018-07-31 0.59 -2.51 1.41 0.52
2018-04-30 0.55 -2.56 1.40 0.48
2018-01-31 0.67 -2.66 1.49 0.49
2017-10-31 0.68 -2.50 1.56 0.24
2017-07-31 0.75 -2.66 1.70 0.29
2017-04-30 -0.36 -4.17 1.90 1.55
2017-01-31 -0.32 -4.63 1.97 1.88
2016-10-31 0.86 -5.06 2.21 2.11
2016-07-31 2.26 -5.16 2.27 2.52
2016-04-30 4.68 -3.66 2.48 1.17
2016-01-31 5.79 -3.30 2.41 0.95
2015-10-31 5.14 -3.36 2.41 1.19
2015-07-31 4.05 -3.50 2.42 0.87
2015-04-30 3.49 -3.29 2.73 0.76
2015-01-31 2.78 -3.66 3.18 0.68
2014-10-31 2.58 -4.04 3.48 0.46
2014-07-31 2.53 -3.84 3.44 0.29
2014-04-30 2.23 -4.23 3.15 0.33
2014-01-31 1.91 -3.88 2.74 0.30
2013-10-31 1.93 -1.38 2.35 0.17
2013-07-31 2.00 -0.40 2.36 0.13
2013-04-30 1.68 8.66 2.22 0.28
2013-01-31 1.54 7.84 2.33 0.20
2012-10-31 1.28 5.43 2.36 0.18
2012-07-31 0.97 3.37 2.43 0.20
2012-04-30 0.95 -6.56 2.30 0.22

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if MedMira has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
  • It is difficult to establish if MedMira has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if MedMira improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
X
Past performance checks
We assess MedMira's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
MedMira has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

47M Health

 How is MedMira's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up MedMira's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • MedMira's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
  • MedMira has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of MedMira's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • MedMira has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from MedMira Company Filings, last reported 2 months ago.

DB:47M Past Debt and Equity Data
Date (Data in CAD Millions) Total Equity Total Debt Cash & Short Term Investments
2019-01-31 -12.54 8.20 0.00
2018-10-31 -11.91 7.98
2018-07-31 -11.40 7.58
2018-04-30 -10.90 7.54
2018-01-31 -10.25 7.41 0.03
2017-10-31 -9.54 7.32 0.12
2017-07-31 -8.98 6.94 0.16
2017-04-30 -8.44 6.64 0.09
2017-01-31 -7.69 6.24 0.12
2016-10-31 -7.67 6.26 0.17
2016-07-31 -7.66 6.25 0.05
2016-04-30 -5.80 5.97 0.21
2016-01-31 -4.59 6.15 1.63
2015-10-31 -3.63 6.46 3.15
2015-07-31 -7.70 6.96 0.26
2015-04-30 -7.41 6.18 0.16
2015-01-31 -7.68 6.63 0.13
2014-10-31 -6.64 6.41 0.53
2014-07-31 -6.69 6.22 0.16
2014-04-30 -6.51 5.78 0.28
2014-01-31 -5.30 6.12 2.43
2013-10-31 -3.88 6.33 4.56
2013-07-31 -9.11 6.87 0.02
2013-04-30 -8.35 6.29 0.02
2013-01-31 -7.49 6.07 0.45
2012-10-31 -8.57 7.82 1.30
2012-07-31 -8.71 7.41 2.42
2012-04-30 -22.91 17.02
  • MedMira has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
  • Irrelevant to check if MedMira's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • MedMira has less than a year of cash runway based on current free cash flow.
  • MedMira has less than a year of cash runway if free cash flow continues to reduce at historical rates of -60.9% each year.
X
Financial health checks
We assess MedMira's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. MedMira has a total score of 1/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

47M Dividends

 What is MedMira's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from MedMira dividends.
If you bought €2,000 of MedMira shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate MedMira's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate MedMira's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:47M Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.5%
Germany Market Average Dividend Yield Market Cap Weighted Average of 324 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.9%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as MedMira has not reported any payouts.
  • Unable to verify if MedMira's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of MedMira's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as MedMira has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess MedMira's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.9%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can MedMira afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. MedMira has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

47M Management

 What is the CEO of MedMira's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Hermes Chan
COMPENSATION CA$191,422
TENURE AS CEO 12.8 years
CEO Bio

Mr. Hermes Chan Co-Founded MedMira Inc. and has been its President since 2000 and Chief Executive Officer since July 24, 2006. Mr. Chan has been the Chief Executive Officer and President of MedMira Laboratories Inc. of MedMira Inc. since July 2006. He served as the Chief Operating Officer of MedMira Inc. since 2000 and MedMira Laboratories Inc. since July 2006. He served as Vice Chairman of MedMira Inc. since 1994. Prior to being appointed as Senior Vice President in 1997, Mr. Chan served as General Manager and as a research scientist with MedMira Laboratories Inc. Prior to joining MedMira Laboratories Inc., Mr. Chan served as a research scientist with Octopus Diagnostic Research, a private diagnostics company located in Wolfville, Nova Scotia. He has been a Director of MedMira Inc. since March 13, 2000.

CEO Compensation
  • Hermes's compensation has been consistent with company performance over the past year.
  • Hermes's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the MedMira management team in years:

5.6
Average Tenure
  • The average tenure for the MedMira management team is over 5 years, this suggests they are a seasoned and experienced team.
Management Team

Hermes Chan

TITLE
Co-Founder
COMPENSATION
CA$191K
TENURE
12.8 yrs

Urs Meile

TITLE
Chief Financial Officer
COMPENSATION
CA$150K
TENURE
4.8 yrs

Stewart McKelvey

TITLE
Legal Counsel

Kevin Jones

TITLE
Head of Commercialization and Senior Director of Sales & Marketing
AGE
49
TENURE
5.6 yrs
Board of Directors Tenure

Average tenure of the MedMira board of directors in years:

2.3
Average Tenure
  • The average tenure for the MedMira board of directors is less than 3 years, this suggests a new board.
Board of Directors

Hermes Chan

TITLE
Co-Founder
COMPENSATION
CA$191K
TENURE
19.1 yrs

Shou-Ching Tang

TITLE
Director
TENURE
2.3 yrs

Lili Zhao

TITLE
Director
TENURE
1.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess MedMira's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. MedMira has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

47M News

Simply Wall St News

47M Company Info

Description

MedMira Inc., a biotechnology company, researches, develops, manufactures, and commercializes rapid diagnostics and technology platforms in North America, Latin America and the Caribbean, Europe, and the Asia Pacific. The company’s research is focused on specific areas of the diagnostics market, such as rapid, point-of-care, and in vitro sectors. It offers Reveal HIV that detects antibodies to HIV-1 and HIV-2 in whole blood, serum, or plasma; and Reveal HP, a rapid H. Pylori antibody test, which detects helicobacter pylori (HP) antibodies in serum, plasma, or whole blood produced in response to HP infection. The company also provides Reveal TP, a rapid syphilis antibody test that detects treponema pallidum antibodies in serum, plasma, or whole blood; and Multiplo, a line of multiplex tests, including combination testing solutions for HIV-1/2, Hepatitis B and C, and Syphilis. In addition, it offers Miriad RVF toolkit that facilitates the development and commercialization of rapid diagnostics. MedMira Inc. sells its products through a network of medical distributors and strategic business development partners with customers in various sectors of the healthcare industry, including laboratories, hospitals, point-of-care facilities, governments, and public health agencies. The company was founded in 1993 and is headquartered in Halifax, Canada. MedMira Inc. is a subsidiary of OnSite Lab Holdings AG.

Details
Name: MedMira Inc.
47M
Exchange: DB
Founded: 1993
CA$6,568,383
658,364,320
Website: http://www.medmira.com
Address: MedMira Inc.
155 Chain Lake Drive,
Suite 1,
Halifax,
Nova Scotia, B3S 1B3,
Canada
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
TSXV MIR Common Shares TSX Venture Exchange CA CAD 15. Mar 2000
OTCPK MMIR.F Common Shares Pink Sheets LLC US USD 15. Mar 2000
DB 47M Common Shares Deutsche Boerse AG DE EUR 15. Mar 2000
Number of employees
Current staff
Staff numbers
0
MedMira employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/18 21:22
End of day share price update: 2019/04/18 00:00
Last earnings filing: 2019/03/29
Last earnings reported: 2019/01/31
Last annual earnings reported: 2018/07/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.